Genomic Expression
June 16, 2025
Company Presentation
Other
RNA AI Platform for Next Generation Cures - because by analyzing RNA, we can detect disease, monitor health, and design the Next Generation Cures
RNA is the cell software, and by decoding it, we can recode biology. Our RNA AI platform not only improves patient outcomes now but fundamentally shifts how we approach cancer treatment and drug discovery and development in the future - potentially bending the cost and time curve for new drug approvals.
The Problem: Despite significant advancements in cancer treatment, the reality remains stark: 50-80% of patients do not benefit from standard of care, with drugs that are expensive to develop.
Our Solution: OneRNA® Platform enables truly individualized treatment by accurately quantifying all RNAs in the sample, statistically powering the results, and connecting the dots to approved drugs that can interrogate the abnormally expressed genes or their product.
Company HQ City:
Beverly
Company HQ State:
MA
Company HQ Country:
United States
Year Founded:
2017
Lead Product in Development:
OneRNA Platform validated in breast and ovarian cancer
CEO
Gitte Pedersen
Year Founded
2017
Development Phase of Lead Product
Other/Not Applicable
Number of Unlicensed Products Looking for Licensing
1
When you expect your next catalyst update?
Launching of OneRNA® as a diagnostic platform and scaling revenue
What is your next catalyst (value inflection) update?
in 2025 Q3
Website
https://www.genomicexpression.com/
Primary Speaker
)
)
)
)
){kind=logo}
)
){kind=logo}